Aylward G W, Claoué C M, Marsh R J, Yasseem N
Bascom Palmer Eye Institute, Miami, FL 33101.
Eye (Lond). 1994;8 ( Pt 1):70-4. doi: 10.1038/eye.1994.13.
The role of oral acyclovir (ACV) in the management of immunocompetent patients with herpes zoster ophthalmicus remains controversial. We have performed a retrospective, comparative, case-control study of cases seen in the Zoster Clinic at Moorfields Eye Hospital over the last 5 years. A standard proforma was used during this period to collect data on the rash, ocular involvement and treatment. There were 419 immunocompetent patients of whom 77 were treated with oral ACV prior to attending the clinic. We compared these with paired controls matched for age, sex and severity of rash. No difference in the rate of ocular complications between treated and untreated patients could be detected. This suggests that oral ACV as currently prescribed has little or no preventive effect on the ocular complications of ophthalmic zoster.
口服阿昔洛韦(ACV)在免疫功能正常的眼部带状疱疹患者治疗中的作用仍存在争议。我们对过去5年在摩尔菲尔德眼科医院带状疱疹诊所就诊的病例进行了一项回顾性、对比性病例对照研究。在此期间,使用标准表格收集有关皮疹、眼部受累情况及治疗的数据。共有419例免疫功能正常的患者,其中77例在就诊前接受了口服ACV治疗。我们将这些患者与在年龄、性别和皮疹严重程度方面相匹配的对照配对进行比较。未发现治疗组和未治疗组患者眼部并发症发生率有差异。这表明,目前所开的口服ACV对眼部带状疱疹的眼部并发症几乎没有预防作用。